You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

November 28, 2017

Thailand Food and Drug Administration Unveils New Official Fees

Subscribe to Updates
Informed Counsel

Higher life expectancy, a growing middle-income population, and the government’s policy of promoting access to medicine are key drivers boosting demand for healthcare-related businesses in Thailand. In 2015, healthcare expenditures accounted for 4.6 percent of Thailand’s GDP, and there is an increasing trend in government budgetary spending in healthcare. Due to these factors, the healthcare market is experiencing strong growth, bringing opportunities in cosmetics, health supplements, medical devices, and pharmaceuticals.

Nonetheless, a major obstacle for these industries is the slow-moving registration process of the Thai Food and Drug Administration (FDA). This registration process is a mandatory prerequisite for introducing new healthcare products to the Thai market.

There are currently thousands of drug registration dossiers under evaluation by the FDA that have been stalled under successive governments. A similar backlog has been found in the process to obtain licenses for moderate- to high-risk medical devices, novel foods, food supplements, and innovative herbal products.

The backlog of pending product approvals hinders industries from competing effectively in the market, and it impacts companies eager to launch their new products in a timely manner. More importantly, from a consumer standpoint, the slow approval process prevents Thais from being able to buy products at lower competitive prices and restricts access to the latest innovative drugs.

Delays in the approval process stem from the fact that the FDA lacks sufficient qualified officers to examine technical dossiers to assess the quality, efficacy, and safety of products. The FDA has difficulty in hiring qualified experts, and there are not enough specialists to handle the ever-increasing number of application dossiers.

Reforming the FDA Approval Process

In order to solve this backlog issue, the prime minister has exercised his power as head of the National Council for Peace and Order (NCPO) by using section 44 of the 2014 interim constitution to issue NCPO Order No. 77/2559 Re: Increasing the Efficiency of the Health Products Approval Process, which was published in the Government Gazette on December 28, 2016. The order directs that the FDA approval process for healthcare products must be reformed. The main implications of the order include the following:

  • The FDA’s product approval timeline must not exceed the time specified in its public manuals, which are handbooks that inform the public about the application procedures, relevant legislation, timelines, and list of documents needed for product registration at the FDA.
  • The FDA will consider the official fee schedule in its approval process. Official fees earned by the FDA will be used as honorariums for reviewers/experts to assess technical dossiers, as well as to improve the approval procedure, as per regulations of the Ministry of Finance. Unlike in the past, official fees earned by the FDA will not be refunded to the Ministry of Finance as government revenue.
  • The FDA will outsource some work, such as onsite inspections and evaluations of technical documents, to external experts of local or overseas agencies, who have been approved by and registered with the FDA.

New FDA Official Fees

The FDA engaged in over 10 meetings with major pharmaceutical companies to discuss the overhaul of its approval process and official fee schedule. Subsequently, the Ministry of Public Health (MoPH) issued MoPH Notification Re: Actual Official Fees in the Approval Process to Be Paid by the Applicant on August 4, 2017. The notification prescribes the highest rates of official fees and actual fees to be paid by applicants, with the highest rates to remain effective for 10 years, and revisions by the FDA allowed in five years.

In the past, the FDA approval process charged only one fee for obtaining a license. The new official fee schedule introduced by the MoPH notification itemizes fees to be incurred for each step of the application process, from filing the application, to dossier evaluation, to obtaining a license.

As of August 4, 2017, an applicant now pays THB 2,500 for filing an application, THB 182,500 for dossier evaluation, and THB 2,000 for obtaining the Marketing Authorization (MA) Drug Product License for a new chemical drug. The MoPH notification also prescribes fees covering the lifecycle of a drug product, including fees for an importation/manufacturing license, a sales license, an advertisement approval license, variations of these licenses, etc. More interestingly, the FDA now charges an hourly consultation fee of THB 500–2,000, depending on the consultation matter.

Healthcare business operators should closely monitor the registration and approval process reforms of the Thai FDA. Although the FDA’s official fees have increased substantially, product owners hoping to bring their new products to the Thai market are likely to benefit greatly from the invigorated registration process that promises drug product approval in a more timely and systematic manner.

Download Full Article
Related Professionals

Industries

Life Sciences

Practices

Regulatory Affairs

Location

RELATED INSIGHTS​ 

April 19, 2022
New technologies and production processes in the food industry have led to novel foods becoming increasingly important to both food manufacturers and the consuming public worldwide. This is very much the case across a number of jurisdictions in Southeast Asia. “Novel foods” refer to new food production processes, foods, and ingredients that have not yet been commonly used for human consumption, so these innovative foods require safety assessments before companies can produce and market them. While rules for these safety assessments are already part of novel food regulations in several other jurisdictions—such as the novel food regulations in the United Kingdom and European Union adopted in 2003, and the major reform of food safety laws in the United States passed in 2011 under the Food Modernization Act—similar rules governing the assessment of novel foods are relatively new or yet to be introduced in many parts of Asia. Nevertheless, it is important to understand the laws and practices that apply to safety assessments and the process of bringing novel foods to market in jurisdictions in the region. This article provides some clarity in this regard by summarizing important practical information on novel foods and the relevant required safety assessments in Indonesia, Thailand, and Vietnam.   Indonesia Regulator National Agency for Drug and Food Control (NADFC); frequently referred to as BPOM (Badan Pengawas Obat dan Makanan). Relevant Measures BPOM Regulation No. 27 Year 2018 concerning Public Service Standards in BPOM; Decision of the Director of Processed Food Standardization No. HK.02.02.51.511.06.21.21 Year 2021 concerning Public Service Standard Directorate Processed Food Standardization Definitions General “food ingredients” are basic fresh or processed ingredients that can be used to produce food; novel food is any food ingredient not listed in BPOM’s positive list of ingredients. Official Fees None   Process and Timeline Before submitting an
Read More
March 31, 2022
Since the onset of the COVID-19 pandemic and the ensuing safety measures, many Thai retailers have shifted their sales toward online platforms. Unsurprisingly, counterfeiters have followed suit. The online sale of counterfeit healthcare and other life sciences products (e.g., food, cosmetics, and medical devices) is an area of significant concern, as it is particularly prevalent, damaging, and complex in relation to Thailand’s laws. This article outlines this type of counterfeiting activity in Thailand and explains some important tools brand owners have for fighting it. Counterfeiting Operations Although illicit operations seek to avoid being identified by authorities and brand owners, investigations by law enforcement and Tilleke & Gibbins on behalf of clients have yielded some insights into how these illegitimate sellers typically operate. Often, consumers are first exposed to these counterfeit life sciences products by paid social media advertisements that link to social media accounts set up by sellers impersonating brand owners. This brand impersonation may include unauthorized use of a trademark or trade name as part of the account name, and unauthorized reproduction of official advertisement artwork or product descriptions, taken directly from the official social media account. From the fake social media account, consumers are usually directed to a merchant website that contains consumer reviews, which are entirely fabricated. While not every counterfeiting operation follows this exact blueprint, employing some variation of these methods lends counterfeiting platforms the ability to proliferate through multiple iterations, as well as believability in the eyes of consumers. How Brand Owners Can Take Action Life sciences brand owners often discover that their products have been targeted by counterfeiters when a counterfeit item injures or negatively impacts a consumer. Thinking that the product is genuine, the consumer may then complain to the brand owner, or worse, file a complaint with the authorities. Many times
Read More
March 15, 2022
Indonesia’s National Agency of Drug and Food Control (BPOM) has recently issued several new regulations governing advertisements for cosmetic products in the country. The main regulation—BPOM Regulation No. 32 of 2021 concerning Cosmetics Advertising—took effect on December 13, 2021, and revokes previous regulations regarding cosmetics advertising from 2016. The key aspects of the new regulation are outlined below. Cosmetic Claims The list of prohibited claims for cosmetic products is no longer included with the regulation. Instead, BPOM issued a stand-alone regulation on cosmetic claims as Regulation No. 3 of 2022, which was enacted on January 7, 2022. This regulation on cosmetic claims contains nonexhaustive lists of prohibited and allowed claims for cosmetic products. The new regulation states that published cosmetics advertisements must correspond to the information on the cosmetic product notification. This differs from the previous regulation, which only stated that published cosmetics advertisements were acceptable as long as they were in accordance with the Technical Guidelines for Cosmetics Advertising. Nonetheless, advertisements for cosmetics still do not have to be approved by BPOM prior to their publication. Publication Media Unlike the previous regulation, which only listed electronic, printed, or outdoor media for publishing advertisements for cosmetic products, the new regulation details six main types of advertising media: Printed media: Gazettes, magazines, tabloids, newspapers, bulletins, posters or flyers, leaflets, stickers, booklets, pamphlets, yellow pages, catalogs, and any other printed media  targeting a limited audience in a certain sector, industry, entity, or profession (i.e., non-mass media). Broadcast media: Television (including running-text classifieds, superimposed ads, and “built-in” ads displayed during a television program), radio, and cinema. Online media: Activities (such as searches of websites and webpages), e-commerce, games, social media (e.g., Instagram, Facebook, Twitter), applications, publications, transportation on demand, display ads, video ads, and entertainment, in various possible formats (such as video,
Read More
March 8, 2022
Attorneys from Tilleke & Gibbins’ offices in Vietnam have contributed the Vietnam chapter to Pharmaceutical Advertising 2022 from Chambers & Partners. Pharmaceutical Advertising 2022—the fifth annual edition of this practice guide—provides information on pharmaceutical advertising regulations in 18 jurisdictions around the world. The guidance is especially useful for pharmaceutical manufacturers looking to share their products and innovations with the public in a responsible, transparent way that is compliant with local laws. The Vietnam chapter specifically the following topics: Regulatory Framework for pharmaceutical advertising Scope of advertising and general principles Advertising of unauthorized medicines or unauthorized indications Advertising pharmaceuticals to the general public Advertising to healthcare professionals Vetting requirements and internal verification compliance Advertising of medicinal products on the internet Inducement and antibribery Gifts, hospitality, congresses and related payments Transparency considerations for pharmaceutical companies Enforcement of pharmaceutical advertising rules Tilleke & Gibbins also provided the Thailand chapter to this guide. Chambers & Partners’ Global Practice Guides provide in-house counsel with expert legal commentary focusing on practical legal issues affecting business, and enable readers to compare legislation and relevant procedures across a range of key jurisdictions. The full Pharmaceutical Advertising 2022 guide—including the Vietnam chapter—is available for free on the Chambers and Partners website. The Vietnam chapter is also available as a PDF through the button below.
Read More